With over 200 employees in Brazil and Mexico, moksha8 is strongly positioned to be the partner of choice for Biotechnology and Pharma companies looking to leverage the value of their product portfolios in Latin America.

moksha8 offers a single 'one-stop-shop' commercialization capability with core strengths in CNS, anti-infective and pain/inflammation therapeutic areas combined with high quality targeting, marketing and promotion to physicians and hospitals. Our commercialization capabilities are supported by rigorous sales and compliance training that allow us to operate at a level of professionalism and integrity that is valued by our partners.

Additionally, moksha8 has strong regulatory capabilities to register and launch novel products in it's key markets. By partnering with moksha8, Biotechnology and Pharma companies can leverage moksha8's expertise to maximize value by expanding the global presence of their products without the need to be 'in market'.

Brazil and Mexico represent over 75% of the $40 billion dollar pharmaceutical market in Latin America with projected growth rates of 11-14% compared to (1)-2% in the US over the next few years.Economies like Brazil and Mexico with growing middle classes seeking access to safe, effective medicines, make these regions an ideal market for high quality pharmaceutical products.